前收市價 | 32.00 |
開市 | 31.12 |
買盤 | 31.10 x 50000 |
賣出價 | 31.40 x 50000 |
今日波幅 | 31.12 - 31.12 |
52 週波幅 | 22.55 - 34.38 |
成交量 | |
平均成交量 | 171 |
市值 | 無 |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | 無 |
業績公佈日 | 2024年7月29日 - 2024年8月02日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
Merck stock tumbled under its 50-day moving average Thursday after the FDA rejected its Daiichi Sankyo-partnered cancer drug.
The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility.
On Wednesday, the FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) seeking accelerated approval of Daiichi Sankyo (OTC:DSKYF) (OTC:DSNKY) and Merck & Co Inc’s (NYSE:MRK) patritumab deruxtecan (HER3-DXd) for adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with two or more systemic therapies. The CRL results from findings about an inspection of a third-party manufacturing facility. The CRL